Does metformin have a disease modifying effect in symptomatic knee osteoarthritis? A multicentre randomised, double-blind, placebo-controlled trial

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1133903

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Osteoarthritis(OA) is a major contributor to this disease burden. Currently, there is no therapy that slows disease progression. Metformin may affect OA progression via multiple pathways that address the pathogenesis of knee OA, including weight loss, glucose- and lipid-lowering, and anti-inflammation. This will be the world first randomised, double-blind controlled trial, to assess the effect of metformin, compared with placebo, on knee OA-related structural and clinical outcomes

Funded Activity Details

Start Date: 01-01-2018

End Date: 01-01-2020

Funding Scheme: Postgraduate Scholarships

Funding Amount: $124,676.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Rheumatology and Arthritis

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

disease progression | knee osteoarthritis | magnetic resonance imaging (MRI) | metabolic syndrome | randomised controlled trial (RCT)

Related Links